Journal of Psychopharmacology

Article	Citations
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	313
Effects of initial nicotine exposure on cognition and nicotine reinforcement among non-smoking young adults with and without attention deficit hyperactivity disorder	231
Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults	152
The chronic effects of a combination of herbal extracts (Euphytose®) on psychological mood state and response to a laboratory stressor: A randomised, placebo-controlled, double blind study	123
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	99
Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a	86
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	81
Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report	69
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	65
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	59
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	58
Glutamate levels across deep brain structures in patients with a psychotic disorder and its relation to cognitive functioning	50
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	48
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	46
Psychedelics and the ‘inner healer’: Myth or mechanism?	46
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	46
Repurposing psychopharmacology: A two-way street?	44
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	43
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	42
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	42
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	41
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	40
The effects of antenatal depression and SSRI exposure on children: A systematic review	38
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	38
Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	38

A framework for assessment of adverse events occurring in psychedelic-assisted therapies	38
Psychedelic research – Going global	37
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms	36
Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment	36
The empathogen 3,4-methylenedioxymethamphetamine, but not methamphetamine, increases feelings of global trust	35
Serotonin release by parachloroamphetamine in rats with high and low sociability: High prefrontal release capacity in sociable females	34
Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains	34
What are set and setting: Reducing vagueness to improve research and clinical practice	34
Corrigendum: Is psychedelic use associated with cancer? Interrogating a half-century-old claim using contemporary population-level data	33
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment	32
Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis	31
The New Zealand drug harms ranking study: A multi-criteria decision analysis	30
Postpartum depression: A role for psychedelics?	30
Not too quick on “Debunking the myth of ‘Blue Mondays’”	30
Elevated C-reactive protein among symptomatic youth with bipolar disorder	30
Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs	29
A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder	28
Wistar Kyoto rats exhibit decreased serotonin neuronal firing and increased norepinephrine burst activity but dampened hippocampal α2-adrenoceptor sensitivity	27
Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study	26
Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program	25
A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)	25
Psychedelic-assisted psychotherapy: The need to monitor adverse events	25
Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19 / CYP2D6 genes play a	24
The mechanism of action of clozapine	24
The low risk for early renal damage during lithium treatment has not changed over time	24
Drug–drug interactions involving classic psychedelics: A systematic review	24
Impact of psychedelics on craving in addiction: A systematic review	23
Statistical limitations of the claimed dose–response in “Dose–response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials”	23
Effect of CannEpil® on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial	22
Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample	22
Hippocampal phase precession is preserved under ketamine, but the range of precession across a theta cycle is reduced	22
Psilocybin for clinical indications: A scoping review	22
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors	22
Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study	22
Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia	22
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression	22
The effects of reserpine on depression: A systematic review	21
Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospec	21
Eight-week antidepressant treatment effects on connectome gradient in first-episode drug-naïve patients with major depressive disorder	21
Evidence-based guidelines for the interpretation of the 9-item Concise Health Risk Tracking – Self-Report (CHRT-SR9) measure of suicidal risk	21
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression	20
The antidepressant effect and safety of non-intranasal esketamine: A systematic review	20
Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia	20
Evaluation of the sedative-motor effects of novel GABAkine imidazodiazepines using quantitative observation techniques in rhesus monkeys	20
Older adults in psychedelic-assisted therapy trials: A systematic review	19
Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?	19
Escitalopram and functional connectivity in major depressive disorder: A systematic review	19
A three-stage strategy for conducting an experimental investigation: A recommendation to improve the reproducibility of reported conclusions	19
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research	18
Examining the role of systemic chronic inflammation in diet and sleep relationship	18

Chronic Cannabis users exhibit altered oscillatory dynamics and functional connectivity serving visuospatial processing	17
Modafinil: A closer look at its theoretical toxicological potential	17
Differences in social brain function in autism spectrum disorder are linked to the serotonin transporter: A randomised placebo-controlled single-dose crossover trial	17
Blackcurrant ( Ribes nigrum L.) improves cholinergic signaling and protects against chronic Scopolamine-induced memory impairment in mice	17
The effects of selective serotonin reuptake inhibitors on memory functioning in older adults: A systematic literature review	17
Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study	17
Exploring the efficacy and safety of a novel standardized ashwagandha (Withania somnifera) root extract (Witholytin®) in adults experiencing high stress and fatigue in a randomized, double-blin	17
Pivotal role of orexin signaling in the posterior paraventricular nucleus of the thalamus during the stress-induced reinstatement of oxycodone-seeking behavior	17
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder	16
A letter to the editor, associated with the article entitled “Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketam	16
Episodic foresight is impaired following acute alcohol intoxication	16
Amphetamine use disorder is associated with striatum hypoactivation during anticipation of loss and reward	16
Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?	16
The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls	15
We need to talk: The urgent conversation on chronic pain, mental health, prescribing patterns and the opioid crisis	15
Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: A randomized, double-blind, placebo-controlled clinical trial	15
Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)	15
Just a gut feeling: Faecal microbiota transplant for treatment of depression – A mini-review	15
Subjectively reported sleep improvement with antipsychotic medications in clinical practice: A systematic review, meta-analysis and meta-regression of moderating factors	15
Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate	14
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up	14
Temporal profile of intranasal oxytocin in the human autonomic nervous system at rest: An electrocardiography and pupillometry study	14
Efficacy and safety of supraphysiologic doses of levothyroxine for patients with bipolar depression in adults: A systematic review	14
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth	14
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study	14
The role of psychopharmacology and cognitive neuroscience in understanding the brain in the treatment of psychiatric disorders and neurological diseases for the benefit of society	14
Concomitant use of antidepressants and classic psychedelics: A scoping review	14
Younger, drunk, and fast: Paradoxical rapid reaction time in hazardous drinkers	13
Recasting the role of electroconvulsive therapy and the electroconvulsive therapy practitioner: For severe illness, not necessarily treatment-resistant depression	13
Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor complexes without affecting neuroplasticity or depressive-like behaviour	13
A randomized, double-blind, placebo-controlled, Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an immediate-release oral ketamine capsule in healthy vo	13
OAV and 5D-ASC for Brazilian Portuguese: A validation and adaptation study	13
The association between N-methyl-d-aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls	13
Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments	13
The psychedelic effects of cannabis: A review of the literature	13
Common protein networks for various drug regimens of major depression are associated with complement and immunity	13
Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: A systematic review and meta-analysis	13
Causes, clinical characteristics, and outcomes of high lithium levels and intoxications: Retrospective analysis of patient records	12
Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database	12
Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights	12
Effects of CYP2D6*4 polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorder	12
Landscape analysis of pre-registered clinical trials involving classical psychedelics	12
The psychopharmacology of mood disorders	12
Sub-anesthetic doses of ketamine increase single cell entrainment in the rat auditory cortex during auditory steady-state response	12
Self-treatment of psychiatric conditions using ketamine: Patterns, characteristics, and retrospective insights	12
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression	11
The interaction between kynurenine pathway, suicidal ideation and augmentation therapy with minocycline in patients with treatment-resistant depression	11
A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects	11
Targeting disrupted networks in schizophrenia: Can muscarinic drugs make a fundamental difference?	11
Ketamine: A new chapter for clinical psychopharmacology?	11
No evidence that post-training dopamine D2 receptor agonism affects fear generalization in male rats	11
Role of chemokines in depression: Highlights on CX 3 CL1/CX 3 CR1 signaling	11
Interactions of alcohol and the benzodiazepine inverse agonist in healthy male volunteers	11
Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis	11
Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature	11
Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part I	11
Mapping acute alcohol effects on bodily sensations: A cross-dimensional interoceptive approach	11
Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice	11
Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice	10
Role of serotonin in modulation of decision-making in Parkinson’s disease	10
Hippocampal and parahippocampal volume and function predict antidepressant response in patients with major depression: A multimodal neuroimaging study	10
Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences	10
Escitalopram should be investigated in anorexia nervosa: Rationale and review of mechanisms	10
Increasing recreational nitrous oxide use: Should we worry? A narrative review	10
Clinical correlates of early onset antipsychotic treatment resistance	10
Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain	10
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science	10
Appraisal of the validity of preclinical investigations to predict the efficacy of psychedelic drugs as fast-acting antidepressants	9
“Too small to succeed?” Rethinking efficacy claims in a solriamfetol trial for ME/CFS	9
Award winning abstracts presented at the 14th Annual International College of Mental Health Pharmacy (CMHP) Conference Glasgow, UK, on 11th and 12th October 2024	9
The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis	9
Psilocybin history, action and reaction: A narrative clinical review	9
Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review	9
Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview	9
Modification of natural tryptamines for the treatment of neuropsychiatric diseases	9
Influence of panic disorder and paroxetine on brain functional hubs in drug-free patients	9
Exploring the impact of MDMA and oxytocin ligands on anxiety and social responses: A comprehensive behavioural and molecular study in the zebrafish model	9
Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression	9
Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics	9
Role of α1-GABAA receptors in the serotonergic dorsal raphe nucleus in models of opioid reward, anxiety, and depression	9

Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression	9
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazol	9
Co-medication with disulfiram markedly increased serum clozapine levels: Two case reports	9
Effect of ashwagandha ( Withania somnifera ) extract with Sominone (Somin-On™) to improve memory in adults with mild cognitive impairment: A randomized, double-blind, pl	9
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020	9
Naturalistic use of psychedelics is associated with longitudinal improvements in anxiety and depression during global crisis times	9
The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: A systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment	8
Efficacy and adverse effect profile of vortioxetine in major depressive disorder: A meta-analysis	8
Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study	8
Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics	8
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study	8
A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction	8
Nucleus accumbens serotonin 1A receptor expression is altered by female reproduction and regulates postpartum affective and caregiving behaviors	8
Influence of GABAA and GABAB receptor activation on auditory sensory gating and its association with anxiety in healthy volunteers	8
Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension	8
Commentary on Cochrane review: “Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder”	8
Metformin efficacy and safety as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled trial	7
Characteristics of poisonings involving ketamine in the United States, 2019–2021	7
Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder	7
Harnessing placebo: Lessons from psychedelic science	7
Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms	7
Roles of the 5-HT1A receptor in zebrafish responses to potential threat and in sociality	7
β -blockers’ neuropsychiatric risks: Overlooked evidence?	7
Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: A systematic review and dose–response model-based network meta-analysis	7
Fluoxetine rescues the depressive-like behaviour induced by reserpine and the altered emotional behaviour induced by nicotine withdrawal in zebrafish: Involvement of tyrosine hydroxylase	7
Severe neutropenia unrelated to clozapine in patients receiving clozapine	7
Antipsychotic polypharmacy and high-dose antipsychotic therapy compared to antipsychotic monotherapy at standard doses in schizophrenia – a systematic review	7
Boosting the ventrolateral periaqueductal gray-ventral tegmental area pathway by disinhibition of group II mGluRs alleviates chronic restraint stress-induced depression-like behavior in mice	7
Reduced attentional lapses in male rats following a combination treatment of low-dose D-serine and atomoxetine	6
Associations of treatment with hypnotics with suicide and attempted suicide: A nationwide cohort study	6
Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study	6
Do antipsychotic drugs shrink the brain? Probably not	6
Impaired face symmetry detection under alcohol, but no ‘beer goggles’ effect	6
Exploring clozapine use in severe psychiatric symptoms associated with autism spectrum disorder: A scoping review	6
Adolescent substance use trajectories are associated with nucleus accumbens functional connectivity	6
Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review	6
The pseudoscience of lithium and suicide: Reanalysis of a misleading meta-analysis	6
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease	6
Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review	6
Individual differences in cocaine-induced conditioned place preference in male rats: Behavioral and transcriptomic evidence	6
Patient perspectives of lithium and quetiapine augmentation treatment in treatment-resistant depression: A qualitative assessment	6
Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis	6
Habitual caffeine intake, genetics and cognitive performance	6
Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder	6
Ketamine for refractory depression: Save the best for last?	5
Hyperdopaminergia in rats is associated with reverse effort-cost dependent performance	5
Impact of childhood adversity on acute subjective effects of stimulant and opioid drugs: Evidence from placebo-controlled studies in healthy volunteers	5
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study	5
Fluoroquinolones and risk of nightmares: A literature review and disproportionality analysis using individual case safety reports from Food and Drug Administration Adverse Event Reporting System datab	5
Award winning abstracts presented at the 12th Annual International College of Mental Health Pharmacy (CMHP) Conference, Northampton, UK on 7th and 8th October 2022	5
Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure	5
Clozapine and the aryl hydrocarbon receptor	5
Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial	5
Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats	5
Pharmacokinetics and pharmacodynamics of sublingual microdosed lysergic acid diethylamide in healthy adult volunteers	5
Combining bioinformatics, network pharmacology and artificial intelligence to predict the target genes of S-ketamine for treating major depressive disorder	5
Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response	5
CYP1A2 genotype-dependent effects of smoking on mirtazapine serum concentrations	5
Clinical effects of CYP2D6 phenoconversion in patients with psychosis	5
Oral sodium oxybate does not alter plasma kisspeptin levels in healthy male volunteers	5
Effects of gamma-aminobutyric acid on working memory and attention: A randomized, double-blinded, placebo-controlled, crossover trial	5
MDMA enhances positive affective responses to social feedback	5
A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABAB receptor, and morphine in recreational opi	5
The relationship between Parkinson’s disease and sexual hyperactivity secondary to drug treatment: A systematic review	5
Subchronic PCP effects on DNA methylation and protein expression of NMDA receptor subunit genes in the prefrontal cortex and hippocampus of female rats	5
Repeated administration of L-alanine to mice reduces behavioural despair and increases hippocampal mammalian target of rapamycin signalling: Analysis of gender and metabolic effects	4
Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression	4
Predicting clozapine dose required to achieve a therapeutic plasma concentration – A comparison of a population algorithm and three algorithms based on gene variant models	4
Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment	4
Individual and combined effects of cannabidiol and Δ9-tetrahydrocannabinol on striato-cortical connectivity in the human brain	4
Antidepressant initiation and the risk of treatment-emergent mania in children and adolescents with depression: A real-world cohort study	4
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review	4
Award winning abstracts presented at The 11th Annual International College of Mental Health Pharmacy (CMHP) Conference. Manchester, UK on 8th and 9th October 2021	4
Facing trauma under the influence of psychedelics: A phenomenological study with Nova rave survivors	4
MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults	4
Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers	4
The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics	4
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience	4
The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication	4
Debunking the myth of ‘Blue Mondays’: No evidence of affect drop after taking clinical MDMA	4
Can cannabinoids alleviate behavioral symptoms in older adults with dementia? A systematic review	4
Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes	4
Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm	4
Association of benzodiazepines, Z-drugs, pregabalin, and melatonin with traffic accidents: A nationwide cohort and case-crossover study in Danish adults	4
The impact of cannabidiol placebo on amygdala-based neural responses to an acute stressor	4
Low-frequency monitoring for community clozapine initiations: A comparative study relative to standard frequency assessments	4
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients	4
To BDZ or not to BDZ? That is the question! Is there reliable scientific evidence for or against using benzodiazepines in the aftermath of potentially traumatic events for the prevention of PTSD? A sy	4
Less is more? A review of psilocybin microdosing	4
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration an	4
A phase 1 study to assess potential interaction between ASP8062 and alcohol in healthy adult subjects	4
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes	4
Belief changes associated with psychedelic use	3
The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia	3
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins	3